UBS Group
RNA

UBS Group’s Atrium Therapeutics RNA Stock Holding History

UBS Group’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$666K Buy
+49,814
New +$700K ﹤0.01% 5858

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
OCAI
O'Connor Alternative Investments New York $1.17B AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group's RNA Position: Q1 2026 in Review

UBS Group opened a new position in Atrium Therapeutics (RNA) in Q1 2026: 49,814 shares worth $666K. The stake represents ﹤0.01% of the portfolio and ranks #5858 among its holdings.

162 funds tracked by Wall St. Rank hold RNA as of Q1 2026.

  • UBS Group held 49,814 shares of Atrium Therapeutics worth $666K as of Q1 2026.
  • Atrium Therapeutics was a new UBS Group position in Q1 2026.
  • Atrium Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5858 holding.
  • 162 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.